Detalhe da pesquisa
1.
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
N Engl J Med
; 383(11): 1018-1027, 2020 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32905674
2.
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Am J Nephrol
; 53(10): 675-686, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36404708
3.
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Am J Nephrol
; 53(10): 687-700, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36423588
4.
Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.
J Am Acad Dermatol
; 74(2): 280-7.e1-3, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26775775
5.
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
J Am Acad Dermatol
; 72(1): 115-22, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25264239
6.
Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.
Mol Diagn Ther
; 27(1): 61-74, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36329366
7.
Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
Blood Adv
; 6(4): 1089-1094, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794179
8.
Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab.
Mol Diagn Ther
; 27(2): 281, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36870041